State boards warn licensees over research-use-only and unapproved GLP-1 peptides

State medical, nursing and pharmacy boards have issued a new wave of warning notices to licensees about the clinical use of peptides, with most aimed at "research use only" products and some treating all non-FDA-approved peptides as unapproved substances whose administration amounts to unprofessional conduct and malpractice ^[1].

The notices went out over the past few weeks, according to a Sept. 3 analysis by the Health Law Alliance, a health care law firm. The firm describes state boards as taking an aggressive stance even as the Food and Drug Administration weighs easing access to some peptides ^[1]. A partial list of states that have issued warnings or taken a more restrictive posture includes Alabama, California, Connecticut, Louisiana, Mississippi, New Jersey, Ohio and South Carolina ^[1]. Licenses have been suspended and practices have lost licenses, the firm writes, though the number of licensees disciplined has not been reported ^[1].

The wording varies by state. Some warnings are limited to research-use-only, or RUO, peptides. Others refer broadly to both RUO and "non-FDA Approved peptides" ^[1]. Mississippi's warning is a joint statement from the state boards of nursing, pharmacy and medicine ^[1]. South Carolina's notice says in part that "a licensed practitioner purchasing, distributing, or dispensing drugs or its components from an unpermitted facility is aiding and abetting unlicensed practices in violating state law involving drugs and may be disciplined for unprofessional conduct" ^[1].

Several notices address how the drugs reach patients. Some advise that delegation through intermediaries such as certified nurse practitioners or physician assistants does not get around a physician's duty, and that shifting responsibility to patients through waivers or disclaimers does not do so either ^[1]. Scope-of-practice violations, such as working without state prescriptive authority or without a collaborative practice agreement, are a common target ^[1]. Some state boards also warn that prescription drugs and drug components must be bought only from an entity licensed by that state's board of pharmacy ^[1].

A separate Aug. 16 analysis by the LLF National Law Firm describes related board activity ^[2]. Nursing and medical boards are bringing joint discipline against registered nurses in med spas, cosmetic dermatology clinics, plastic surgery offices and wellness clinics who dispense or administer GLP-1 drugs through pre-signed prescription pads or standing orders, charging the nurses with practicing medicine without a license and their supervising physicians with aiding and abetting unlicensed practice ^[2]. Boards are also investigating telehealth practices that let registered nurses evaluate patients or dispense GLP-1s without a prescriber's direct order; registered nurses lack independent prescribing authority in all 50 states ^[2]. Licensing and scope-of-practice rules apply where the patient is physically located, not where the provider is ^[2].

That analysis says pharmacists who buy peptides marked "research use only," often from unverified overseas suppliers, typically face an emergency suspension order from their state pharmacy board, because boards require active pharmaceutical ingredients to be pharmaceutical grade, backed by a valid certificate of analysis and sourced from FDA-registered facilities ^[2].

At the federal level, an FDA advisory panel recommended last month that six peptides be added to the 503A Bulks List, which would allow them to eventually be compounded; some observers view that as an effort to slow the gray market for peptides ^[1]. FDA and consumer protection agencies have also increased enforcement of deceptive marketing and stepped up seizures of imported peptides ^[1].

Why it matters for patients

The warnings target research-use-only and non-FDA-approved peptides. The approved brand-name products — Ozempic, Wegovy and Rybelsus (semaglutide) and Mounjaro and Zepbound (tirzepatide) — are not described as the subject of these notices ^[1][2].

The practical effect falls on compounded and clinic-supplied versions of GLP-1 drugs. If a prescriber or pharmacy loses a license, a telehealth platform or med spa may change what it offers or stop serving a state, and the notices give no stated transition period for patients ^[1]. Because delegation and patient waivers do not shift responsibility under these warnings, a signed consent form at a clinic does not by itself mean the arrangement is permitted ^[1].

Research-use-only peptides are a specific concern: boards treat them as lacking the certificate of analysis and FDA-registered sourcing they require for ingredients ^[2]. What recourse patients have if a supplier is suspended has not been disclosed ^[1][2].

What happens next

The FDA advisory panel's recommendation on six peptides is not a final rule, and whether or when the agency adds them to the 503A Bulks List has not been reported ^[1]. Which additional states might issue notices, and whether any state will rescind or narrow its warning, has not been disclosed ^[1]. Federal enforcement activity on peptide marketing and imports is described as ongoing, without a published schedule ^[1].